Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247417 | 0.93 | MEN1 (0.49) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3263409 | 0.91 | MEN1 (0.46) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3251947 | 0.86 | ICMT (0.47) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3277878 | 0.84 | PLK4 (0.52) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3250429 | 0.80 | PLK4 (0.49) | HDAC1HDAC6CA12CA1CA2 | |
| Hemibastadinol 1 SCHEMBL3255108 | 0.78 | PLK4 (0.49) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3996984 | 0.78 | SMN1; SMN2 (0.59) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3780865 | 0.78 | HDAC1 (0.59) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL15319511 | 0.78 | CA12 (0.56) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL13405154 | 0.76 | LMNA (0.56) | LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700522-B2 | α-Oxygenated or α-thiolated carboxylic acid phenethylamide derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2010-04-20 | — | — | US | claimed |
| US-20050038082-A1 | Novel $g(a)-oxygenated or $g(a)-thiolated carboxylic acid phenethylamide derivatives | SYNGENTA CROP PROTECTION, INC. | 2005-02-17 | — | — | US | claimed |
| EP-1448514-B1 | NOVEL ALPHA-OXYGENATED CARBOXYLIC ACID PHENETHYLAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-7700522-B2 | α-Oxygenated or α-thiolated carboxylic acid phenethylamide derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20050038082-A1 | Novel $g(a)-oxygenated or $g(a)-thiolated carboxylic acid phenethylamide derivatives | SYNGENTA CROP PROTECTION, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1448514-A1 | NOVEL ALPHA-OXYGENATED OR ALPHA-THIOLATED CARBOXYLIC ACID PHENETHYLAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042168-A1 | NOVEL α-OXYGENATED OR α-THIOLATED CARBOXYLIC ACID PHENETHYLAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038082-A1 | Novel $g(a)-oxygenated or $g(a)-thiolated carboxylic acid phenethylamide derivatives | CBR3, CBR1, GLRA1 | HDAC1 1807/4885HDAC6 1022/4885CA12 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.